Mismatches between donor and recipient for human platelet antigens (HPA) may affect the success of transplantation due to: (a) serving as minor histocompatibility antigens and therefore render recipients at risk for graft-versus-host disease (GvHD), (b) inhibition of thrombopoiesis due to platelet antibodies. We therefore evaluated the occurrence of GvHD and need of platelet support by prospective analysis of donor-recipient pairs (n ¼ 53) for HPA-1, -2, -3, and -5 allotypes and screening for platelet antibodies prior to transplantation and in weekly intervals until day 100 after transplantation. Neither the incidence of GvHD nor the onset of thrombopoiesis, nor the CCI after platelet transfusions, nor the frequency of platelet transfusions was affected by HPA mismatches. Settings of homozygous donors vs heterozygous recipients or homozygous recipients vs heterozygous donors were not associated with any adverse effects on the outcome of the transplantation. Thus, the HPA-match does not affect the success of transplantation.
Matching of HLA antigens is considered of utmost importance for the success of allogeneic stem cell transplantation (SCT). Polymorphisms of blood group ABO or human platelet antigens (HPA) are not linked to those of the HLA complex, and therefore even grafts from HLAidentical siblings may differ for ABO or HPA. ABO blood group incompatibility in allogeneic peripheral blood stem cell transplantation (PBSCT) or bone marrow transplantation (BMT) is known to have no clinical relevance for white blood cell or platelet engraftment, but is associated with shorter survival and increased incidence of graft-versushost disease (GvHD), as well as an increased incidence of prolonged pure red cell aplasia (PRCA), or delayed hemolysis. [1] [2] [3] Minor histocompatibility antigens may also significantly affect the success of transplantation and HPA polymorphisms may serve as such minor histocompatibility antigens. 4 In Caucasoids, most alloimmunizations occur against alleles of HPA-1, -2, -3, and -5 resulting in neonatal alloimmune thrombocytopenia, or refractoriness to platelet transfusions, or post-transfusion-purpura. 5, 6 Whether or not these polymorphisms are associated with an increased risk or thromboembolic diseases is controversial. 5, [7] [8] [9] To the best of our knowledge, the influence of HPA mismatches on the clinical outcome of BMT or PBSCT in terms of megakaryocyte reconstitution, the need of platelet support, or GvHD has not been investigated, so far. In unrelated BMT, however, a mismatch for HPA-5 has been proposed to decrease disease free survival. 10 Further, after successful engraftment anti-HPA mediated host-versus-donor reactions have been reported to have caused severe thrombocytopenia. 11, 12 These observations prompted us to investigate if mismatches within the HPA-1, -2, -3, and -5 system influence the clinical course after transplantation, that is, acute GvHD, recovery of thrombopoiesis, and the need of platelet support.
Patients and methods

Patients
In a prospective analysis we evaluated the influence of recipient-donor mismatches for the platelet alloantigens HPA-1, -2, -3, and -5 on the engraftment, the need of platelet and red cell transfusions and GvHD in patients undergoing allogeneic SCT during the first 100 days after transplantation. A total of 26 patients (14 females and 12 males, median age 39 years, range 20-53 years) and 27 patients (14 females and 13 males, median age 41 years, range 17-56 years) received bone marrow (BM) and, peripheral blood stem cells (PBSC) respectively, from HLA A,B,C, and DR (DRB1 and DQB1 alleles typed by nucleotide sequencing of exon 2) identical siblings. Table 1 . For GvHD prophylaxis, 44 patients received cyclosporin A (CsA) and methotrexate (MTX) according to the Seattle protocol and nine patients CsA alone. One recipient, who was transplanted with a graft from her syngenic twin did not get any GvHD prophylaxis. Patients were hospitalized in isolation rooms with laminar airflow or reverse isolation until they reached an absolute neutrophil count (ANC) of more than 0.5 Â 10 9 /l on 3 consecutive days. They received antimicrobial prophylaxis with nonabsorbable antibiotics, Pneumocystis carinii prophylaxis with comitroxazole and cytomegalovirus (CMV) prophylaxis with acyclovir. All patients received leukocyte depleted, irradiated (30 Gy) packed red blood cell concentrates (PRBCs) to maintain a hemoglobin level above 8.0 g/dl and single donor CMV negative, leukocyte-depleted irradiated (30 Gy) platelet concentrates (PCs) to maintain a platelet count above 20 Â 10 9 /L. Peripheral blood (PB) and reticulocyte counts were determined daily, starting 7 days before PBSCT or BMT until sustained hematopoietic engraftment, and then weekly until day 100. Hematological reconstitution was defined as ANC 40.5 Â 10 9 /l, sustained platelet counts without platelet support above 20 Â 10 9 /l, reticulocyte counts 41% and independence of PRBCs transfusions.
Method
Recipients and donors were genotyped for HPA-1, -2, -3, and -5 by PCR-SSP 13 and were screened for the presence of platelet antibodies using panel platelets from blood group O donors homozygous for HPA-1a/b, -2a/b, -3a/b, and -5a/b by the MAIPA technique, and the presence of HLA class I antibodies as described previously.
14,15 Furthermore, platelets from the graft donor and recipients' sera were investigated by a crossmatch by the MAIPA technique using mAb for immunoprecipitation GPIIb/IIIa, GPIb/IX, and GPIa/IIa. Platelet-associated antibodies (PAIgG) were detected by direct MAIPA. The patients' sera were also screened in weekly intervals for the presence of platelet antibodies against GPIa, GPIIb/IIIa, Ib/IX, and HLA by MAIPA. The platelet count was obtained 18-20 h after transfusions. The post transfusion platelet increment (CCI) was calculated as published. 16 
Statistical analyses
Results are expressed as median and range. Because of the non-normal distribution of data all comparisons were made by nonparametric statistics. Statistical analyses were carried out with the Mann-Whitney U-test and the Kruskall-Wallis test and if appropriate with the w 2 test. Analyses included the evaluation of association between the various clinical parameters, like GvHD, with a particular HPA match. A P-value of less than 0.05 was considered significant.
Results
Bone marrow engraftment
All 53 patients had a complete donor leukocyte engraftment within median 17 days (range: 6-29 days) and platelet engraftment was achieved in 52 patients within 18 days (range 8-45 days). One patient needed platelet transfusions until death and was therefore not evaluable for platelet engraftment. BM aspirates on day 28 and 100 after transplantation revealed a sustained trilineage engraftment in the surviving patients (n ¼ 50), who were all free of disease at that latter time-point.
Transplant-related mortality
Two patients suffered from CMV infection and died due to multiple organ failure on day þ 84 and day þ 98, respectively. One patient developed a graft failure on day 73 after transplantation and died on day þ 94. In all, 50 patients survived beyond day 100 after transplantation.
HPA match (Table 2)
Patients were grouped based on the number of mismatches within the HPA-1, -2, -3, or -5 system between donor and recipient (group 1: no mismatch n ¼ 18, including the patient who died on day 94), group 2: one mismatch (n ¼ 21, including the patient who died on day 98), group 3: two mismatches (n ¼ 14, including the patient who died on day 84). As expected, based on the gene frequency in our population, 17 mismatches were most common within the HPA-3 system and least common within the HPA-2 system. Three crossmatches were positive. One patient had HPA-2a antibodies and the donor was heterozygous HPA-2 a/b. In the second case, the positive crossmatch was due to panreactive antibodies against the glycoproteins IIb/IIIa and Ib/IX. No antibodies were detected in the third recipient, but recipient and donor were ABO minor incompatible (O-A) and mismatched for HPA-5. One patient had HPA-3b antibodies, but recipient and donor were homozygous for HPA-3a. In three patients, autoantibodies against the glycoproteins IIb/IIIa (n ¼ 3) and Ib/IX (n ¼ 2) were detected by direct MAIPA, but crossmatches between recipients and donors were negative. In another four patients, the MAIPA revealed HLA class I antibodies, but no reactions with the graft donors. None of the recipients' sera contained new antibodies during the observation period as determined by screening the sera in weekly intervals.
Grouping by the HPA-match did not reveal a difference either for thrombopoietic engraftment or for any of the other hematopoietic lineages (Table 2) .
GvHD and transfusion requirements
Significantly more PCs (median 8, range 3-64) were required if BMs rather then PBSCs (median 4, range 1-57) served as grafts (Po0.05). No such difference was seen for the requirement of PRBC transfusions (median 8, range 2-40 vs median 6, range 2-66). GvHD grade I and grade II-III were diagnosed in 14 and 19 patients, respectively (Table 2) . Neither the frequency of GvHD nor the requirements of PC or PRBC support were increased in patients with HPA-mismatches. As expected, patients with GvHD grade II and III needed more PRBC transfusions than patients without GvHD or grade I (median 14, range 4-66 vs 8, range 2-14 Po0.05). Of note, only four patients had GvHD grade III. Grouping by the HPA-match had no influence on the CCI, and there was no significant difference for platelet recovery (Table 2 ). To investigate whether or not the direction of mismatches influences the development of GvHD, the CCI, platelet requirement, and platelet engraftment we separately evaluated for homozygosity among donors vs those among recipients. However, homozygosity in neither direction was associated with an increased incidence of GvHD. None of any particular HPA mismatch was associated with either the development of GvHD or with its severity.
Discussion
We have addressed the effect of HPA-1, -2, -3 and -5 matching between graft donor and host on GvHD and thrombopoiesis after allogeneic SCT. Thereby, we observed no difference between recipients receiving HPA-matched or HPA-mismatched grafts. Subgroup analysis also revealed no difference with respect of the incidence or severity of GvHD.
It has been shown that GvHD significantly affects the recovery of thrombopoiesis after transplantation. In the donor (homozygous) vs host (one or more mismatches) setting HPA may serve as minor antigens, thus inducing, or, enhancing GvHD. Our data and those from a previous report, 10 however, indicate that HPA-matching is irrelevant for the development of GvHD. Thus, it is unlikely that HPA alone serve as minor histocompatibility antigens becoming responsible for the development of GvHD. In the above-mentioned previous study, the authors have analyzed the data from a large cohort of recipients who were unrelated to their donors. 10 In contrast to that previous investigation, we analyzed only recipients receiving grafts from HLA-matched siblings. Thus, HLA-related incompatibilities can largely be excluded to have affected our results.
Endothelial cells are particularly affected by GvHD. Cultured endothelial cells were found to express HPA-1 and -5 antigens. 18, 19 The endothelium may therefore become a specific target due to HPA incompatibility. However, HPA mismatches of recipient-donor pairs were not associated with an induction/enhancement of GvHD.
Platelet antibodies have been detected in some patients undergoing allogeneic PBSC transplantations 11, 12, [20] [21] [22] [23] These were graft-or host-derived. Donor cells have been shown to produce platelet antibodies shortly after transplantation. These antibodies can significantly affect the increment of HPA-mismatched PCs if they are unselected, resulting in an increased demand. We, however, detected allospecific HPA antibodies in two recipients prior to transplantation. We did not select specifically for compatible donors. It may be that the antibodies' activity waned during the course of transplantation due to myeloablative therapy and therefore no effect of the antibodies on the CCI was noted. A development of new antibodies was not seen when patients' sera were screened in weekly intervals. We cannot exclude that these may have been at too low titers to be detected, in particular if absorbed from the circulation by repeated transfusions of incompatible PCs. 24 
Table 2
Engraftment data, incidence of GvHD, transfusion requirements and CCI in groups 1-3 It is noteworthy, however, that host-derived lymphocytes, which resist myeloablative therapy, may become active and thus produce platelet antibodies that opsonize donorderived platelets inducing their removal from the circulation. 11, 12 Platelet antibodies may not only render patients at risk for bleeding because of refractoriness to platelet transfusions, but can also inhibit thrombopoiesis. For instance, it has been shown that autoantibodies and alloantibodies can bind to megakaryocytes and therefore induce amegakaryocytosis. 25, 26 The development of platelet antibodies, be it donor or, host-derived, following allogeneic SCT after myeloablative conditioning is rare, however, and therefore in our study neither engraftment of thrombopoiesis nor the requirement of PCs was significantly affected by the HPA-match.
In summary, our data from HLA identical recipientdonor pairs do not support a hypothesis that HPAmismatches have adverse effects for the recipient, be it GvHD or impaired thrombopoiesis and increased requirement of platelet support.
